SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MulhollandDrive who wrote (650)9/3/1997 10:44:00 AM
From: Andrew H   of 2173
 
OFF TOPIC--Betty--sorry to take up the thread with LGND news as I read your conversation with Henry. Just checked the Neorx thread--the only reference was to a previous source which has apparently proved accurate before. For me, that gives the rumor more credibility. No one in his right mind would cite a credible source for such info, since it is clearly not public info as yet.

It makes a lot of sense when you think about it. As you may be aware, the large pharms are in the position of having many of their leading drugs go off patent. They are starting to look around to the development stage bios to prop up their pipelines. With AMLN and LGND, J and J would have a substantial position in a huge and lucrative market. And they could hedge their bets in regard to Type 11 diabetes where pramlintide's efficacy has recently been called into question.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News